AR018139A1 - Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. - Google Patents

Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.

Info

Publication number
AR018139A1
AR018139A1 ARP990100880A ARP990100880A AR018139A1 AR 018139 A1 AR018139 A1 AR 018139A1 AR P990100880 A ARP990100880 A AR P990100880A AR P990100880 A ARP990100880 A AR P990100880A AR 018139 A1 AR018139 A1 AR 018139A1
Authority
AR
Argentina
Prior art keywords
hidroxi
halo
manufacture
same
glici
Prior art date
Application number
ARP990100880A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR018139A1 publication Critical patent/AR018139A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de la formula (I) y a las sales aceptables para uso farmacéutico y a los isomeros de los mismos,donde X e Y son el mismo o diferente grupo halo. R es hidrogeno o alquilo C1-6. También se revela la composicion farmacéutica que lo contieney su uso en la fabricacion de medicamentos utiles para el tratamiento de afecciones mediadas por avbeta3 por inhibicion o antagonismo de lasintegrinas avbeta3.
ARP990100880A 1998-03-04 1999-03-02 Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento. AR018139A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3427098A 1998-03-04 1998-03-04

Publications (1)

Publication Number Publication Date
AR018139A1 true AR018139A1 (es) 2001-10-31

Family

ID=21875345

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100880A AR018139A1 (es) 1998-03-04 1999-03-02 Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.

Country Status (29)

Country Link
EP (1) EP1060164A1 (es)
JP (1) JP2002505323A (es)
KR (1) KR20010041584A (es)
CN (1) CN1214011C (es)
AP (1) AP1244A (es)
AR (1) AR018139A1 (es)
AU (1) AU753230B2 (es)
BG (1) BG104740A (es)
BR (1) BR9908470A (es)
CA (1) CA2322207A1 (es)
EA (1) EA200000804A1 (es)
EE (1) EE200000506A (es)
GE (1) GEP20033118B (es)
HR (1) HRP20000574A2 (es)
HU (1) HUP0100865A3 (es)
ID (1) ID25591A (es)
IL (1) IL137653A0 (es)
IS (1) IS5582A (es)
MY (1) MY123908A (es)
NO (1) NO315703B1 (es)
NZ (1) NZ506598A (es)
OA (1) OA11530A (es)
PL (1) PL342726A1 (es)
SK (1) SK13002000A3 (es)
TR (1) TR200002542T2 (es)
UA (1) UA71906C2 (es)
WO (1) WO1999044994A1 (es)
YU (1) YU52000A (es)
ZA (1) ZA994406B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6921767B2 (en) * 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
CA2417059A1 (en) 2000-08-02 2002-02-07 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
CA2510050A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
KR20080031266A (ko) * 2005-06-10 2008-04-08 바이파 사이언스 인코포레이티드 Ｐａｒｐ 조절제 및 암의 치료
EP2131861A2 (en) 2007-03-01 2009-12-16 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
JP4792124B1 (ja) * 2010-11-15 2011-10-12 エフイートレード株式会社 車両用保護フィルムの型取り方法、及び、車両用保護フィルムの製造方法
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
US9856201B2 (en) * 2014-06-04 2018-01-02 Monsanto Technology Llc 3,6-dichlorosalicylic acid compounds and related synthetic processes
SG11201805387RA (en) 2015-12-30 2018-07-30 Univ Saint Louis Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
MX2022014200A (es) 2020-05-14 2022-12-07 Ube Corp Derivado de 1,4,5,6-tetrahidropirimidin-2-amina.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
JPWO2023085396A1 (es) 2021-11-12 2023-05-19

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203234T1 (de) * 1995-08-30 2001-08-15 Searle & Co Meta-guanidine, harnstoff, thioharnstoff oder azacyklische aminobenzoesäure-derivate als integrin antagonisten

Also Published As

Publication number Publication date
NO20004316L (no) 2000-11-06
WO1999044994A1 (en) 1999-09-10
IS5582A (is) 2000-08-04
MY123908A (en) 2006-06-30
BR9908470A (pt) 2000-12-05
YU52000A (sh) 2003-02-28
EE200000506A (et) 2002-04-15
CA2322207A1 (en) 1999-09-10
IL137653A0 (en) 2001-10-31
BG104740A (en) 2001-02-28
AU3294799A (en) 1999-09-20
HUP0100865A2 (hu) 2001-08-28
HUP0100865A3 (en) 2001-11-28
ZA994406B (en) 2000-02-11
JP2002505323A (ja) 2002-02-19
KR20010041584A (ko) 2001-05-25
AP1244A (en) 2004-02-04
CN1214011C (zh) 2005-08-10
HRP20000574A2 (en) 2001-08-31
PL342726A1 (en) 2001-07-02
CN1291978A (zh) 2001-04-18
NO20004316D0 (no) 2000-08-30
OA11530A (en) 2004-05-17
ID25591A (id) 2000-10-19
TR200002542T2 (tr) 2001-05-21
EP1060164A1 (en) 2000-12-20
SK13002000A3 (sk) 2001-07-10
NO315703B1 (no) 2003-10-13
GEP20033118B (en) 2003-11-25
EA200000804A1 (ru) 2001-04-23
AP2000001893A0 (en) 2000-09-30
NZ506598A (en) 2003-07-25
UA71906C2 (en) 2005-01-17
AU753230B2 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
ECSP034732A (es) Derivado de fenetanolamina para el tratamiento de enfermedades respiratorias
PA8547701A1 (es) Nucleosidos 4 substituidos.
BR0111263A (pt) Derivados de 2-aminocarbonil-9h-purina
DE60330910D1 (de) Verbindungen mit selektiverinhibierender wirkung für gsk3
AR032877A1 (es) Inhibidores alquil c(1-6)-4-amino-azepan-3-onicos de proteasas, composiciones farmaceuticas que los comprenden, intermediarios utiles en la preparacion de tales compuestos, procedimiento para la sintesis de dichos inhibidores, y uso de dichos inhibidores en la fabricacion de medicamentos
AR026173A1 (es) Inhibidores de neuraminidasas.
ES2058527T3 (es) Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
BRPI0417458A (pt) compostos inibidores de dpp-iv, sais faramaceuticamente aceitáveis e pró-fármacos do mesmo, seus processos de preparação, composição farmacêutica compreendendo os mesmos e uso dos referidos compostos na fabricação de medicamento
AR035792A1 (es) Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
AR029403A1 (es) Derivados n-sustituidos de carbamoiloxialquil-azolio,un proceso para su fabricacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
BR0113234A (pt) Polimorfos de um análogo de epotilona
UY26872A1 (es) Derivados de la 4- fenil piridina
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
ATE406893T1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
ES2158778B1 (es) Compuestos de sales de paroxetina, su preparacion y uso, y composiciones farmaceuticas que los contienen.
AR003440A1 (es) Nuevos derivados de aminoacidos, formulacion farmaceutica que los contiene, uso de dichos derivados para preparar medicamentos y procedimiento para la preparacion de dichos derivados.
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
UY27700A1 (es) Compuestos oxo - azabiclícos.
AR004961A1 (es) Modificacion cristalina v del clorhidrato de(r)-(-)-2-{n-[4-(1,1-dioxido-3- oxo-2,3-dihidro-benzisotiazol-2-il)-butil]-aminometil)cromano, unprocedimiento para su preparacion, medicamentos que lo contienen, el uso de dicho clorhidrato para la preparacion de medicamentos, una composicion para el

Legal Events

Date Code Title Description
FB Suspension of granting procedure